Patrick J. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patrick J. Smith has a total of 278 co-authors. Here are the top co-authors by number of shared publications:
James A. Blumenthal
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
15 shared publications- Scott M. Palmer
Department of Medicine, Duke University, Durham, NC
11 shared publications - Laurie D. Snyder
Division of Pulmonary Allergy and Critical Care Medicine Department of Medicine Duke University Medical Center Durham North Carolina USA
8 shared publications Andrew Sherwood
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham
7 shared publicationsBenson M. Hoffman
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
5 shared publicationsAlan Hinderliter
Department of Medicine, University of North Carolina at Chapel Hill, NC, USA
4 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Time restricted eating through self-regulatory behaviors for metabolic and cognitive health in mild cognitive impairment: Feasibility and acceptability findings from the TEMPO trial
Background: Mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD) occur at 1.5–2-fold higher rates among adults with obesity or metabolic syndrome. Time restricted eating (TRE) represents a portable and potentially effective strategy to enhance metabolic function and reduce ADRD risk. Objective: To assess the feasibility and acceptability of TRE among older adults with MCI and metabolic risk. Methods: We assessed a 16–18-h TRE protocol, implemented 2–3 days per week, among older adults (65–85 years of age) with MCI (proposed n = 40) and metabolic risk over 12-weeks. Feasibility was assessed by recruitment and completion of trial activities, while Acceptability was assessed using psychometric self-report. Cognitive function was assessed using a standard neuropsychological test battery, including tests of Executive Function/Processing Speed (Trail Making, Stroop, Controlled Oral Word Association Test, Animal Naming, Digit Span, and Digit Symbol Substitution Tests), Learning/Memory (Hopkins Verbal Learning Test–Revised and Benton Visual Memory Test–Revised. We also examined treatment- and state-dependent changes in metabolic and inflammatory biomarkers, including multiple ketone metabolites and pro-inflammatory cytokines, among others. Results: From 9/28/23 until 3/25/25, thirty-three individuals (83% of target goal [n = 40]) were recruited. Enrolled participants completed all treatment sessions and assessments (100%) and self-reported Acceptability was high. Modification of study recruitment practices and inclusion criteria allowed for an increased screening-to-recruitment ratios over the course of the trial, rising from 1.3% to 11.1%, while still resulting in appropriate recruitment of individuals with MCI. Conclusions: TRE is a feasible and acceptable intervention among older adults with metabolic risk factors.
- 22 October 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Open AccessTime restricted eating through self-regulatory behaviors for metabolic and cognitive health in mild cognitive impairment: Feasibility and acceptability findings from the TEMPO trial
Background: Mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD) occur at 1.5–2-fold higher rates among adults with obesity or metabolic syndrome. Time restricted eating (TRE) represents a portable and potentially effective strategy to enhance metabolic function and reduce ADRD risk. Objective: To assess the feasibility and acceptability of TRE among older adults with MCI and metabolic risk. Methods: We assessed a 16–18-h TRE protocol, implemented 2–3 days per week, among older adults (65–85 years of age) with MCI (proposed n = 40) and metabolic risk over 12-weeks. Feasibility was assessed by recruitment and completion of trial activities, while Acceptability was assessed using psychometric self-report. Cognitive function was assessed using a standard neuropsychological test battery, including tests of Executive Function/Processing Speed (Trail Making, Stroop, Controlled Oral Word Association Test, Animal Naming, Digit Span, and Digit Symbol Substitution Tests), Learning/Memory (Hopkins Verbal Learning Test–Revised and Benton Visual Memory Test–Revised. We also examined treatment- and state-dependent changes in metabolic and inflammatory biomarkers, including multiple ketone metabolites and pro-inflammatory cytokines, among others. Results: From 9/28/23 until 3/25/25, thirty-three individuals (83% of target goal [n = 40]) were recruited. Enrolled participants completed all treatment sessions and assessments (100%) and self-reported Acceptability was high. Modification of study recruitment practices and inclusion criteria allowed for an increased screening-to-recruitment ratios over the course of the trial, rising from 1.3% to 11.1%, while still resulting in appropriate recruitment of individuals with MCI. Conclusions: TRE is a feasible and acceptable intervention among older adults with metabolic risk factors.
- 10 August 2026
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- p. 1-9
Cognitive workload and its relationship with neurocognitive performance before and after breast cancer chemotherapy
Objectives: To compare associations between neurocognitive testing and two different self-report paradigms: (1) recall-based (PROMIS Cognitive Function) and (2) real-time, task-specific (NASA-Task Load Index [NASA-TLX]) among 56 patients with breast cancer. Methods: This is a secondary analysis from a phase II, single-arm trial of memantine to prevent cognitive decline among patients receiving chemotherapy for breast cancer (NCT04033419). Before chemotherapy and 4 weeks after their final cycle, participants completed neuropsychological assessment and self-report measures. Memantine was administered between assessments. At pre-chemotherapy, multivariable linear regression evaluated associations between a unit-weighted, composite neurocognitive test score with PROMIS Cognitive Function and NASA-TLX, controlling for age, cancer stage, and cognitive reserve. Explanatory analyses examined associations within individual neurocognitive subtests. Multivariable regression explored the extent to which pre-treatment self-reported cognition predicted post-treatment performance. Results: Pre-chemotherapy, higher NASA-TLX scores (greater perceived workload) were robustly associated with worse performance ( β = −0.31 [−0.50, −0.12], p = .002). Relationships were strongest for executive function: Animal Fluency (IQR = 35): −3.3 (−5.8, −0.8), p = .011; COWA (IQR = 36) = −6.7 (−12.8, −0.7), p = .031; One Touch Stockings (IQR = 31): −0.70 (−1.0, −0.3), p < .001. Pre-treatment NASA-TLX was also associated with post-treatment performance in univariable but not multivariable models. PROMIS Cognitive Function and neurocognitive performance were not associated. Conclusions: The NASA-TLX and neurocognitive performance were strongly associated, particularly in the executive function domain. Future work involving the NASA-TLX in cancer populations, including its use in everyday contexts, will help clarify whether it may enhance CRCI characterization.
- 10 August 2026
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- p. 1-9
Cognitive workload and its relationship with neurocognitive performance before and after breast cancer chemotherapy
Objectives: To compare associations between neurocognitive testing and two different self-report paradigms: (1) recall-based (PROMIS Cognitive Function) and (2) real-time, task-specific (NASA-Task Load Index [NASA-TLX]) among 56 patients with breast cancer. Methods: This is a secondary analysis from a phase II, single-arm trial of memantine to prevent cognitive decline among patients receiving chemotherapy for breast cancer (NCT04033419). Before chemotherapy and 4 weeks after their final cycle, participants completed neuropsychological assessment and self-report measures. Memantine was administered between assessments. At pre-chemotherapy, multivariable linear regression evaluated associations between a unit-weighted, composite neurocognitive test score with PROMIS Cognitive Function and NASA-TLX, controlling for age, cancer stage, and cognitive reserve. Explanatory analyses examined associations within individual neurocognitive subtests. Multivariable regression explored the extent to which pre-treatment self-reported cognition predicted post-treatment performance. Results: Pre-chemotherapy, higher NASA-TLX scores (greater perceived workload) were robustly associated with worse performance ( β = −0.31 [−0.50, −0.12], p = .002). Relationships were strongest for executive function: Animal Fluency (IQR = 35): −3.3 (−5.8, −0.8), p = .011; COWA (IQR = 36) = −6.7 (−12.8, −0.7), p = .031; One Touch Stockings (IQR = 31): −0.70 (−1.0, −0.3), p < .001. Pre-treatment NASA-TLX was also associated with post-treatment performance in univariable but not multivariable models. PROMIS Cognitive Function and neurocognitive performance were not associated. Conclusions: The NASA-TLX and neurocognitive performance were strongly associated, particularly in the executive function domain. Future work involving the NASA-TLX in cancer populations, including its use in everyday contexts, will help clarify whether it may enhance CRCI characterization.
- Top Cited PapersOpen Access
- 31 March 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (5)
Clinical predictors of resilience following total knee arthroplasty: the PRIME-KNEE study
Background: We aimed to describe recovery trajectories over 6 months in pain intensity, pain interference, lower extremity disability, and physical activity in older adults undergoing elective total knee arthroplasty (TKA), and to identify clinically feasible measures predicting recovery. Methods: Prospective cohort study in a single academic medical center. Adults ≥60 years (n = 203) scheduled for elective TKA had preoperative assessments of physical reserve (3-min walk test, grip strength), psychological reserve (PHQ-9, Resilience Scale), social support (emotional support scale, financial resource sufficiency, education level), and cognitive reserve (3MS, Trail Making Test Part B, Digit Symbol Substitution Test, 15-item recall). Provocative tests with experimental stressors included dual-task gait speed, and functional near infrared spectroscopy (fNIRS). Outcomes were the PROMIS pain scales, the lower extremity gain scale, and average daily step counts measured at postoperative day 1-7 and months 1, 2, 4, and 6. Latent class trajectory analysis defined common recovery patterns for each outcome. Results: For each outcome, 3-4 recovery trajectory groups were defined. Overall, 7% of participants were in the highest recovery group in all 4 outcomes and 20% in the lowest for all outcomes. Preoperative depression score, cognitive tests, emotional support scale, 3-min walk distance, and grip strength were significantly different across resilience groups in multiple outcomes. Provocative tests were not predictive of recovery. Conclusions: Recovery trajectories after TKA are predicted by physical, cognitive, and psychological reserve measures. Results inform future resilience research and may allow for shared decision-making and targeted preoperative optimization.
- 31 March 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (5)
Top Cited PapersOpen AccessClinical predictors of resilience following total knee arthroplasty: the PRIME-KNEE study
Background: We aimed to describe recovery trajectories over 6 months in pain intensity, pain interference, lower extremity disability, and physical activity in older adults undergoing elective total knee arthroplasty (TKA), and to identify clinically feasible measures predicting recovery. Methods: Prospective cohort study in a single academic medical center. Adults ≥60 years (n = 203) scheduled for elective TKA had preoperative assessments of physical reserve (3-min walk test, grip strength), psychological reserve (PHQ-9, Resilience Scale), social support (emotional support scale, financial resource sufficiency, education level), and cognitive reserve (3MS, Trail Making Test Part B, Digit Symbol Substitution Test, 15-item recall). Provocative tests with experimental stressors included dual-task gait speed, and functional near infrared spectroscopy (fNIRS). Outcomes were the PROMIS pain scales, the lower extremity gain scale, and average daily step counts measured at postoperative day 1-7 and months 1, 2, 4, and 6. Latent class trajectory analysis defined common recovery patterns for each outcome. Results: For each outcome, 3-4 recovery trajectory groups were defined. Overall, 7% of participants were in the highest recovery group in all 4 outcomes and 20% in the lowest for all outcomes. Preoperative depression score, cognitive tests, emotional support scale, 3-min walk distance, and grip strength were significantly different across resilience groups in multiple outcomes. Provocative tests were not predictive of recovery. Conclusions: Recovery trajectories after TKA are predicted by physical, cognitive, and psychological reserve measures. Results inform future resilience research and may allow for shared decision-making and targeted preoperative optimization.
- Open Access
- 20 January 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (4) , 1748-1763
Lifestyle, sleep quality, and cognitive function in resistant hypertension: One-year follow-up from the TRIUMPH trial
Background: Treatment resistant hypertension (TRH) is associated with increased risk of cognitive decline, which may be reduced by healthy lifestyle changes. Objective: To examine the effects of a comprehensive, rehabilitation-based lifestyle hprogram on cognitive function during a one-year follow-up of participants from the TRIUMPH clinical trial. Methods: Among the 140 TRIUMPH participants originally randomized, 91 (65%) were available for one-year assessments prior to the COVID-19 lockdown. Participants were originally randomized to a C ardiac rehabilitation-based LIFE style program (C-LIFE) or to a S tandardized E ducation and P hysician A dvice (SEPA) condition for 4-months. During their one-year follow-up, participants underwent assessments of sleep quality, body mass index, actigraphy-assessed physical activity levels, and cerebrovascular reactivity using functional near infrared spectroscopy (fNIRS). Cognitive function was assessed using a 45-min test battery incorporating tests of Executive Function/Learning, Memory, and Processing Speed. Regression-based models incorporating reliable change indices were used to assess cognitive change. Results: Participants included 91 individuals (mean age = 63.6 [SD = 8.6]), evenly distributed in biological sex and race/ethnicity, and tended to be college-educated. The C-LIFE group had more preserved cognitive functioning compared to SEPA (C-LIFE: z = −0.26 [−0.40, −0.12] versus SEPA: −0.60 [−0.81, −0.39]; d = 0.44, p = 0.008), with reduced PSQI sleep symptoms associating with more preserved cognitive function (B = −0.18, p = 0.050 per 3-points). Treatment did not improve fNIRS markers, although changes in weight and physical activity associated with fNIRS outcomes. Conclusions: Lifestyle modification may help preserve cognitive functioning among individuals with resistant hypertension.
- 20 January 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (4) , 1748-1763
Open AccessLifestyle, sleep quality, and cognitive function in resistant hypertension: One-year follow-up from the TRIUMPH trial
Background: Treatment resistant hypertension (TRH) is associated with increased risk of cognitive decline, which may be reduced by healthy lifestyle changes. Objective: To examine the effects of a comprehensive, rehabilitation-based lifestyle hprogram on cognitive function during a one-year follow-up of participants from the TRIUMPH clinical trial. Methods: Among the 140 TRIUMPH participants originally randomized, 91 (65%) were available for one-year assessments prior to the COVID-19 lockdown. Participants were originally randomized to a C ardiac rehabilitation-based LIFE style program (C-LIFE) or to a S tandardized E ducation and P hysician A dvice (SEPA) condition for 4-months. During their one-year follow-up, participants underwent assessments of sleep quality, body mass index, actigraphy-assessed physical activity levels, and cerebrovascular reactivity using functional near infrared spectroscopy (fNIRS). Cognitive function was assessed using a 45-min test battery incorporating tests of Executive Function/Learning, Memory, and Processing Speed. Regression-based models incorporating reliable change indices were used to assess cognitive change. Results: Participants included 91 individuals (mean age = 63.6 [SD = 8.6]), evenly distributed in biological sex and race/ethnicity, and tended to be college-educated. The C-LIFE group had more preserved cognitive functioning compared to SEPA (C-LIFE: z = −0.26 [−0.40, −0.12] versus SEPA: −0.60 [−0.81, −0.39]; d = 0.44, p = 0.008), with reduced PSQI sleep symptoms associating with more preserved cognitive function (B = −0.18, p = 0.050 per 3-points). Treatment did not improve fNIRS markers, although changes in weight and physical activity associated with fNIRS outcomes. Conclusions: Lifestyle modification may help preserve cognitive functioning among individuals with resistant hypertension.
- 16 January 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 168-171
Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement
- 16 January 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 168-171
Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement
- 20 December 2025
- Published by Oxford University Press (OUP) in Archives of Clinical Neuropsychology
- Vol. 41 (3)
Ambulatory Cognitive Function and Cognitive Dispersion among Individuals with Type I Diabetes: Examining Biobehavioral and Glycemic Correlates
Aims: Diabetes mellitus (DM) is widely regarded as an important risk factor for Alzheimer’s Disease and Related Dementias (ADRD), with higher blood glucose variability (BGV) associating with greater ADRD risk. Few studies have linked BGV with ambulatory cognitive functioning or cognitive dispersion measures in T1DM. Materials and Methods: We conducted a pilot study in which 20 individuals with type-I DM (T1DM) wore a continuous glucose monitor and actigraphy monitor for one week while completing ambulatory measures of cognition. In addition to ambulatory measures, participants completed a 45-min neuropsychological battery consisting of eight standard measures of Executive Functioning, Memory and Learning, and premorbid intellectual functioning. Demographically corrected t-scores were obtained, as well as measures of cognitive dispersion. Results: Cardiovascular risk factors and markers of metabolic function were associated with cognitive function and cognitive dispersion. Higher glucose levels, HbA1c, and body mass, as well as lower physical activity and sleep efficiency all associated with worse ambulatory cognition. Conclusions: Ambulatory cognitive measures demonstrated robust associations with clinical neuropsychological measures and dynamic associations with ambulatory metabolic function and health behaviors. Greater levels of cognitive dispersion associated with vascular risk factors, worse metabolic function, and worse ambulatory cognitive functioning.
- 20 December 2025
- Published by Oxford University Press (OUP) in Archives of Clinical Neuropsychology
- Vol. 41 (3)
Ambulatory Cognitive Function and Cognitive Dispersion among Individuals with Type I Diabetes: Examining Biobehavioral and Glycemic Correlates
Aims: Diabetes mellitus (DM) is widely regarded as an important risk factor for Alzheimer’s Disease and Related Dementias (ADRD), with higher blood glucose variability (BGV) associating with greater ADRD risk. Few studies have linked BGV with ambulatory cognitive functioning or cognitive dispersion measures in T1DM. Materials and Methods: We conducted a pilot study in which 20 individuals with type-I DM (T1DM) wore a continuous glucose monitor and actigraphy monitor for one week while completing ambulatory measures of cognition. In addition to ambulatory measures, participants completed a 45-min neuropsychological battery consisting of eight standard measures of Executive Functioning, Memory and Learning, and premorbid intellectual functioning. Demographically corrected t-scores were obtained, as well as measures of cognitive dispersion. Results: Cardiovascular risk factors and markers of metabolic function were associated with cognitive function and cognitive dispersion. Higher glucose levels, HbA1c, and body mass, as well as lower physical activity and sleep efficiency all associated with worse ambulatory cognition. Conclusions: Ambulatory cognitive measures demonstrated robust associations with clinical neuropsychological measures and dynamic associations with ambulatory metabolic function and health behaviors. Greater levels of cognitive dispersion associated with vascular risk factors, worse metabolic function, and worse ambulatory cognitive functioning.
- 24 March 2025
- Published by Wolters Kluwer Health in Biopsychosocial Science and Medicine
- Vol. 87 (4) , 271-279
Psychological Flexibility, Coping Styles, and Mood among individuals with Cystic Fibrosis
Objective: An emerging body of evidence suggests that psychological flexibility may be an important and underexamined determinant of overall psychological functioning. The chronic nature of Cystic Fibrosis (CF) may require a greater level of flexibility to navigate complex and dynamic health concerns in an increasingly aging population. Methods: We examined associations between psychological flexibility, coping styles, psychological grit, and negative affectivity (anxiety and depressive symptoms) from baseline assessments of randomized trial among adults with CF. Regression models controlling for age, gender, income, psychotropic medication use and pulmonary function were used to characterize associations between psychological flexibility, coping styles and negative affect. Results: A total of 124 individuals were included in analyses, 74 (60%) of whom were taking a psychotropic medication. Depressive (BDI-II=18.6 [SD=9.9]) and anxious (BAI=13.8 [SD=9.3]) symptoms were both elevated. Greater levels of psychological flexibility were associated with lower negative affect, such that individuals reporting less cognitive fusion (B=−0.59, PPP1/FVC levels. Conclusions: Psychological flexibility is robustly associated with decreased negative affect among individuals with CF, independent of background and clinical characteristics.
- 24 March 2025
- Published by Wolters Kluwer Health in Biopsychosocial Science and Medicine
- Vol. 87 (4) , 271-279
Psychological Flexibility, Coping Styles, and Mood among individuals with Cystic Fibrosis
Objective: An emerging body of evidence suggests that psychological flexibility may be an important and underexamined determinant of overall psychological functioning. The chronic nature of Cystic Fibrosis (CF) may require a greater level of flexibility to navigate complex and dynamic health concerns in an increasingly aging population. Methods: We examined associations between psychological flexibility, coping styles, psychological grit, and negative affectivity (anxiety and depressive symptoms) from baseline assessments of randomized trial among adults with CF. Regression models controlling for age, gender, income, psychotropic medication use and pulmonary function were used to characterize associations between psychological flexibility, coping styles and negative affect. Results: A total of 124 individuals were included in analyses, 74 (60%) of whom were taking a psychotropic medication. Depressive (BDI-II=18.6 [SD=9.9]) and anxious (BAI=13.8 [SD=9.3]) symptoms were both elevated. Greater levels of psychological flexibility were associated with lower negative affect, such that individuals reporting less cognitive fusion (B=−0.59, PPP1/FVC levels. Conclusions: Psychological flexibility is robustly associated with decreased negative affect among individuals with CF, independent of background and clinical characteristics.
- Open Access
- 11 March 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 26 (4) , 441-447
Cognitive behavior therapy for insomnia for untreated hypertension with comorbid insomnia disorder: The SLEEPRIGHT clinical trial
Insomnia and poor sleep are associated with an increased risk of developing cardiovascular disease (CVD) and its precursors, including hypertension. In 2022, the American Heart Association (AHA) added inadequate sleep to its list of health behaviors that increase the risk for CVD. It remains unknown, however, whether the successful treatment of insomnia and inadequate sleep can reduce heightened CVD risk. SLEEPRIGHT is a single‐site, prospective clinical trial designed to evaluate whether the successful treatment of insomnia results in improved markers of CVD risk in patients with untreated hypertension and comorbid insomnia disorder. Participants (N = 150) will undergo baseline assessments, followed by a 6‐week run‐in period after which they will receive cognitive behavior therapy for insomnia (CBT‐I), comprised of 6 hourly sessions with an experienced CBT‐I therapist over a 6‐week period. In addition to measures of insomnia severity, as well as both subjective and objective measures of sleep, the primary outcome measures are nighttime blood pressure (BP) and BP dipping assessed by 24‐h ambulatory BP monitoring (ABPM). Secondary outcomes include several CVD risk biomarkers, including clinic BP, lipid profile, vascular endothelial function, arterial stiffness, and sympathetic nervous system (SNS) activity. Data analysis will evaluate the association between improvements in insomnia and sleep with primary and secondary CVD risk biomarker outcomes. The SLEEPRIGHT trial (ClinicalTrials.Gov NCT04009447) will utilize CBT‐I, the current gold standard treatment for insomnia disorder, to evaluate whether reducing insomnia severity and improving sleep are accompanied by improved biomarkers of CVD risk in patients with untreated hypertension.
- 11 March 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 26 (4) , 441-447
Open AccessCognitive behavior therapy for insomnia for untreated hypertension with comorbid insomnia disorder: The SLEEPRIGHT clinical trial
Insomnia and poor sleep are associated with an increased risk of developing cardiovascular disease (CVD) and its precursors, including hypertension. In 2022, the American Heart Association (AHA) added inadequate sleep to its list of health behaviors that increase the risk for CVD. It remains unknown, however, whether the successful treatment of insomnia and inadequate sleep can reduce heightened CVD risk. SLEEPRIGHT is a single‐site, prospective clinical trial designed to evaluate whether the successful treatment of insomnia results in improved markers of CVD risk in patients with untreated hypertension and comorbid insomnia disorder. Participants (N = 150) will undergo baseline assessments, followed by a 6‐week run‐in period after which they will receive cognitive behavior therapy for insomnia (CBT‐I), comprised of 6 hourly sessions with an experienced CBT‐I therapist over a 6‐week period. In addition to measures of insomnia severity, as well as both subjective and objective measures of sleep, the primary outcome measures are nighttime blood pressure (BP) and BP dipping assessed by 24‐h ambulatory BP monitoring (ABPM). Secondary outcomes include several CVD risk biomarkers, including clinic BP, lipid profile, vascular endothelial function, arterial stiffness, and sympathetic nervous system (SNS) activity. Data analysis will evaluate the association between improvements in insomnia and sleep with primary and secondary CVD risk biomarker outcomes. The SLEEPRIGHT trial (ClinicalTrials.Gov NCT04009447) will utilize CBT‐I, the current gold standard treatment for insomnia disorder, to evaluate whether reducing insomnia severity and improving sleep are accompanied by improved biomarkers of CVD risk in patients with untreated hypertension.
- 11 May 2023
- Published by Taylor & Francis
- p. 145-160
Exercise and Physical Activity in the Prevention and Treatment of Depression
Depression is a term that refers both to a transient mood state and a clinical syndrome or disorder. As a mood state, depression is characterized by feeling despondent or unhappy, while depression as a mood disorder is a persistent set of symptoms as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). Specifically, major depressive disorder (MDD) is a psychiatric condition in which diagnostic criteria require five or more depressive symptoms, one of which must include either depressed mood or loss of interest or pleasure. Other depressive symptoms include significant weight loss, sleep changes (i.e., insomnia or hypersomnia), psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, and recurrent thoughts of death. MDD is also distinguished from normal symptoms of sadness by criteria for symptom severity and duration: symptoms of depression must have been present during the same two-week period, be present all or most of the time, and represent a change from a previous level of functioning.
- 11 May 2023
- Published by Taylor & Francis
- p. 145-160
Exercise and Physical Activity in the Prevention and Treatment of Depression
Depression is a term that refers both to a transient mood state and a clinical syndrome or disorder. As a mood state, depression is characterized by feeling despondent or unhappy, while depression as a mood disorder is a persistent set of symptoms as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). Specifically, major depressive disorder (MDD) is a psychiatric condition in which diagnostic criteria require five or more depressive symptoms, one of which must include either depressed mood or loss of interest or pleasure. Other depressive symptoms include significant weight loss, sleep changes (i.e., insomnia or hypersomnia), psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, and recurrent thoughts of death. MDD is also distinguished from normal symptoms of sadness by criteria for symptom severity and duration: symptoms of depression must have been present during the same two-week period, be present all or most of the time, and represent a change from a previous level of functioning.
- 10 June 2022
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 40 (7) , 1359-1368
Lifestyle modification and cognitive function among individuals with resistant hypertension: cognitive outcomes from the TRIUMPH trial
Background: Resistant hypertension is associated with increased risk of cognitive decline, stroke, and dementia. Lifestyle modification has been suggested to improve cognitive function through its salutary effects on vascular function. Methods: Participants included 140 patients with resistant hypertension participating in the TRIUMPH trial. Participants were randomized to a cardiac rehabilitation-based lifestyle program (C-LIFE) or a standardized education and physician advice condition (SEPA). Participants completed a 45-min cognitive test battery consisting of tests of Executive Functioning and Learning, Memory, and Processing Speed. Biomarkers of vascular [flow mediated dilation of the brachial artery (FMD)], microvascular, and cerebrovascular function were also collected, in addition to weight, fitness, and ambulatory blood pressure. Results: Participants averaged 63 years of age, 48% women, 59% black, and obese [mean BMI = 36 kg/m2 (SD = 4)]. Cognitive performance improved across the entire cohort during the 4-month trial [t-scores pretreatment = 48.9 (48, 50) vs. posttreatment = 50.0 (49, 51), P < 0.001]. Postintervention Executive Function/Learning composite performance was higher for participants in C-LIFE compared to SEPA (d = 0.37, P = 0.039). C-LIFE intervention effects on Memory and Processing Speed were moderated by sex and baseline stroke risk, respectively (P = 0.026 and P = 0.043 for interactions), such that males and participants with greater stroke risk showed the greatest cognitive changes. FMD [C-LIFE: +0.3% (−0.3, 1.0) vs. SEPA: −1.4% (−2.5, −0.3), P = 0.022], and microvascular function [C-LIFE: 97 (65, 130) vs. SEPA: 025 (−75, 23), P < 0.001] were improved in C-LIFE compared with SEPA, whereas cerebrovascular reactivity was not [C-LIFE: −0.2 (−0.4, 0) vs. SEPA: 0.1 (−0.2, 0.4), P = 0.197). Mediation analyses suggested that increased executive function/learning was associated with reduced ambulatory SBP levels secondary to weight loss [indirect effect: B = 0.25 (0.03, 0.71)]. Conclusion: Lifestyle modification individuals with resistant hypertension improves cognition, which appeared to be associated with reduced ambulatory SBP changes through weight loss. Cognitive improvements were accompanied by parallel improvements in endothelial and microvascular function.
- 10 June 2022
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 40 (7) , 1359-1368
Lifestyle modification and cognitive function among individuals with resistant hypertension: cognitive outcomes from the TRIUMPH trial
Background: Resistant hypertension is associated with increased risk of cognitive decline, stroke, and dementia. Lifestyle modification has been suggested to improve cognitive function through its salutary effects on vascular function. Methods: Participants included 140 patients with resistant hypertension participating in the TRIUMPH trial. Participants were randomized to a cardiac rehabilitation-based lifestyle program (C-LIFE) or a standardized education and physician advice condition (SEPA). Participants completed a 45-min cognitive test battery consisting of tests of Executive Functioning and Learning, Memory, and Processing Speed. Biomarkers of vascular [flow mediated dilation of the brachial artery (FMD)], microvascular, and cerebrovascular function were also collected, in addition to weight, fitness, and ambulatory blood pressure. Results: Participants averaged 63 years of age, 48% women, 59% black, and obese [mean BMI = 36 kg/m2 (SD = 4)]. Cognitive performance improved across the entire cohort during the 4-month trial [t-scores pretreatment = 48.9 (48, 50) vs. posttreatment = 50.0 (49, 51), P < 0.001]. Postintervention Executive Function/Learning composite performance was higher for participants in C-LIFE compared to SEPA (d = 0.37, P = 0.039). C-LIFE intervention effects on Memory and Processing Speed were moderated by sex and baseline stroke risk, respectively (P = 0.026 and P = 0.043 for interactions), such that males and participants with greater stroke risk showed the greatest cognitive changes. FMD [C-LIFE: +0.3% (−0.3, 1.0) vs. SEPA: −1.4% (−2.5, −0.3), P = 0.022], and microvascular function [C-LIFE: 97 (65, 130) vs. SEPA: 025 (−75, 23), P < 0.001] were improved in C-LIFE compared with SEPA, whereas cerebrovascular reactivity was not [C-LIFE: −0.2 (−0.4, 0) vs. SEPA: 0.1 (−0.2, 0.4), P = 0.197). Mediation analyses suggested that increased executive function/learning was associated with reduced ambulatory SBP levels secondary to weight loss [indirect effect: B = 0.25 (0.03, 0.71)]. Conclusion: Lifestyle modification individuals with resistant hypertension improves cognition, which appeared to be associated with reduced ambulatory SBP changes through weight loss. Cognitive improvements were accompanied by parallel improvements in endothelial and microvascular function.